{"id":66734,"date":"2026-05-29T21:17:09","date_gmt":"2026-05-29T13:17:09","guid":{"rendered":"https:\/\/flcube.com\/?p=66734"},"modified":"2026-05-29T21:17:10","modified_gmt":"2026-05-29T13:17:10","slug":"innocare-pharmas-btk-inhibitor-orelabrutinib-gains-nmpa-review-acceptance-for-primary-immune-thrombocytopenia-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66734","title":{"rendered":"InnoCare Pharma&#8217;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>InnoCare Pharma Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>) announced that the <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review a new indication filing for its <strong>orelabrutinib<\/strong>, a <strong>Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/strong>, as a treatment for <strong>primary immune thrombocytopenia (ITP)<\/strong>. This marks a significant expansion of the drug&#8217;s therapeutic profile beyond its current oncology indications.<\/p>\n\n\n\n<h2 id=\"h-regulatory-status-amp-current-approvals\" class=\"wp-block-heading\">Regulatory Status &amp; Current Approvals<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Accepted for review<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Primary immune thrombocytopenia (ITP)<\/td><\/tr><tr><td><strong>Current Approved Indications in China:<\/strong><\/td><td><\/td><\/tr><tr><td>\u2022 Chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)<\/td><td>\u2713<\/td><\/tr><tr><td>\u2022 Marginal zone lymphoma (MZL)<\/td><td>\u2713<\/td><\/tr><tr><td>\u2022 Mantle cell lymphoma (MCL)<\/td><td>\u2713<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-therapeutic-expansion\" class=\"wp-block-heading\">Drug Profile &amp; Therapeutic Expansion<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> Selective Bruton&#8217;s tyrosine kinase (BTK) inhibitor<\/li>\n\n\n\n<li><strong>Mechanism in Autoimmunity:<\/strong> Modulates B-cell receptor signaling and Fc\u03b3 receptor-mediated pathways involved in autoimmune platelet destruction<\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> Prior studies demonstrated favorable efficacy and safety in autoimmune diseases including ITP<\/li>\n\n\n\n<li><strong>Therapeutic Strategy:<\/strong> Leverages established safety profile from oncology use to address autoimmune conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-broader-autoimmune-development-pipeline\" class=\"wp-block-heading\">Broader Autoimmune Development Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Development Stage<\/th><th>Geography<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Immune Thrombocytopenia (ITP)<\/strong><\/td><td>Registration filing<\/td><td>China<\/td><td><strong>NMPA review accepted<\/strong><\/td><\/tr><tr><td><strong>Systemic Lupus Erythematosus (SLE)<\/strong><\/td><td>Phase III registrational<\/td><td>China and global<\/td><td>Actively underway<\/td><\/tr><tr><td><strong>Primary Progressive Multiple Sclerosis (PPMS)<\/strong><\/td><td>Phase III registrational<\/td><td>China and global<\/td><td>Actively underway<\/td><\/tr><tr><td><strong>Secondary Progressive Multiple Sclerosis (SPMS)<\/strong><\/td><td>Phase III registrational<\/td><td>China and global<\/td><td>Actively underway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-analysis\" class=\"wp-block-heading\">Market Opportunity Analysis<\/h2>\n\n\n\n<h3 id=\"h-primary-immune-thrombocytopenia-landscape\" class=\"wp-block-heading\">Primary Immune Thrombocytopenia Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> Estimated 150,000-200,000 ITP patients in China with significant unmet need<\/li>\n\n\n\n<li><strong>Current Treatment Limitations:<\/strong><\/li>\n\n\n\n<li>Corticosteroids: Significant long-term toxicity<\/li>\n\n\n\n<li>Splenectomy: Invasive with permanent consequences<\/li>\n\n\n\n<li>Thrombopoietin receptor agonists: High cost, variable response<\/li>\n\n\n\n<li><strong>BTK Inhibitor Advantage:<\/strong> Oral administration, targeted mechanism, potential for durable responses<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-btk-inhibitors-in-autoimmunity\" class=\"wp-block-heading\">Competitive BTK Inhibitors in Autoimmunity<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>ITP Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Orelabrutinib<\/strong><\/td><td>InnoCare Pharma<\/td><td><strong>NMPA review<\/strong><\/td><td>China-first approval, established safety<\/td><\/tr><tr><td><strong>Fenebrutinib<\/strong><\/td><td>Roche<\/td><td>Phase III<\/td><td>Global development<\/td><\/tr><tr><td><strong>Evobrutinib<\/strong><\/td><td>Merck KGaA<\/td><td>Phase III<\/td><td>Multiple sclerosis focus<\/td><\/tr><tr><td><strong>Rilzabrutinib<\/strong><\/td><td>Sanofi<\/td><td>Phase III<\/td><td>Reversible BTK inhibition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-innocare-pharma\" class=\"wp-block-heading\">For InnoCare Pharma<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Expansion:<\/strong> Transforms orelabrutinib from oncology-only to dual oncology\/autoimmunity franchise<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Autoimmune indications represent larger patient populations than current hematologic malignancies<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> Early mover advantage in Chinese autoimmune BTK inhibitor market<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in China could support international regulatory filings<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-china-autoimmune-therapy-market-dynamics\" class=\"wp-block-heading\">China Autoimmune Therapy Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High Unmet Need:<\/strong> Limited innovative therapies approved for autoimmune conditions<\/li>\n\n\n\n<li><strong>Healthcare Policy Support:<\/strong> Government prioritizes domestic innovative drugs for chronic diseases<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Local manufacturing enables competitive pricing vs. imported biologics<\/li>\n\n\n\n<li><strong>Physician Adoption:<\/strong> Established orelabrutinib safety profile facilitates rapid uptake in new indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial potential for orelabrutinib. Actual results may differ due to risks including NMPA approval decisions, clinical trial outcomes, market competition, and evolving treatment guidelines for autoimmune diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052800536_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052800536_c.\"><\/object><a id=\"wp-block-file--media-8c97f8f4-1cd5-4085-9769-2b26528a157d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052800536_c.pdf\">2026052800536_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052800536_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8c97f8f4-1cd5-4085-9769-2b26528a157d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,919,327,38,920,33],"class_list":["post-66734","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-hkg-9969","tag-innocare-pharma","tag-market-approval-filings","tag-sha-688428","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma&#039;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) has accepted for review a new indication filing for its orelabrutinib, a Bruton&#039;s tyrosine kinase (BTK) inhibitor, as a treatment for primary immune thrombocytopenia (ITP). This marks a significant expansion of the drug&#039;s therapeutic profile beyond its current oncology indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66734\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma&#039;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) has accepted for review a new indication filing for its orelabrutinib, a Bruton&#039;s tyrosine kinase (BTK) inhibitor, as a treatment for primary immune thrombocytopenia (ITP). This marks a significant expansion of the drug&#039;s therapeutic profile beyond its current oncology indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66734\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T13:17:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T13:17:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66734#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66734\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma&#8217;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication\",\"datePublished\":\"2026-05-29T13:17:09+00:00\",\"dateModified\":\"2026-05-29T13:17:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66734\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"HKG: 9969\",\"InnoCare Pharma\",\"Market approval filings\",\"SHA: 688428\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66734#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66734\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66734\",\"name\":\"InnoCare Pharma's BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T13:17:09+00:00\",\"dateModified\":\"2026-05-29T13:17:10+00:00\",\"description\":\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, as a treatment for primary immune thrombocytopenia (ITP). This marks a significant expansion of the drug's therapeutic profile beyond its current oncology indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66734#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66734\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66734#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma&#8217;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma's BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, as a treatment for primary immune thrombocytopenia (ITP). This marks a significant expansion of the drug's therapeutic profile beyond its current oncology indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66734","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma's BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication","og_description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, as a treatment for primary immune thrombocytopenia (ITP). This marks a significant expansion of the drug's therapeutic profile beyond its current oncology indications.","og_url":"https:\/\/flcube.com\/?p=66734","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T13:17:09+00:00","article_modified_time":"2026-05-29T13:17:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66734#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66734"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma&#8217;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication","datePublished":"2026-05-29T13:17:09+00:00","dateModified":"2026-05-29T13:17:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66734"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","HKG: 9969","InnoCare Pharma","Market approval filings","SHA: 688428","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66734#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66734","url":"https:\/\/flcube.com\/?p=66734","name":"InnoCare Pharma's BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T13:17:09+00:00","dateModified":"2026-05-29T13:17:10+00:00","description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted for review a new indication filing for its orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, as a treatment for primary immune thrombocytopenia (ITP). This marks a significant expansion of the drug's therapeutic profile beyond its current oncology indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66734#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66734"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66734#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma&#8217;s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66734"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66734\/revisions"}],"predecessor-version":[{"id":66736,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66734\/revisions\/66736"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}